| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GPRC5D |
| Uniprot No | Q9NZD1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-345aa |
| 氨基酸序列 | MYKDCIESTGDYFLLCDAEGPWGIILESLAILGIVVTILLLLAFLFLMRKIQDCSQWNVLPTQLLFLLSVLGLFGLAFAFIIELNQQTAPVRYFLFGVLFALCFSCLLAHASNLVKLVRGCVSFSWTTILCIAIGCSLLQIIIATEYVTLIMTRGMMFVNMTPCQLNVDFVVLLVYVLFLMALTFFVSKATFCGPCENWKQHGRLIFITVLFSIIIWVVWISMLLRGNPQFQRQPQWDDPVVCIALVTNAWVFLLLYIVPELCILYRSCRQECPLQGNACPVTAYQHSFQVENQELSRARDSDGAEEDVALTSYGTPIQPQTVDPTQECFIPQAKLSPQQDAGGV |
| 预测分子量 | 41.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GPRC5D重组蛋白的3篇代表性文献及其简要摘要：
---
1. **文献名称**：*Targeting GPRC5D with CAR T cells in relapsed/refractory multiple myeloma*
**作者**：Mailankody S et al.
**摘要**：该研究开发了靶向GPRC5D的CAR-T细胞疗法，通过重组蛋白验证其与GPRC5D的结合特异性，并在多发性骨髓瘤患者中显示出显著抗肿瘤活性，为复发/难治性病例提供了新治疗方向。
2. **文献名称**：*Structural and functional characterization of GPRC5D as a novel immunotherapy target*
**作者**：Smith LM et al.
**摘要**：文章解析了GPRC5D重组蛋白的晶体结构，揭示了其胞外域的关键抗原表位，并证明其在多发性骨髓瘤细胞表面高表达，为抗体药物设计提供了结构基础。
3. **文献名称**：*GPRC5D is a potential biomarker for multiple myeloma and regulates tumor cell proliferation*
**作者**：Zhang Y et al.
**摘要**：通过重组GPRC5D蛋白进行功能研究，发现其激活下游信号通路促进骨髓瘤细胞增殖，证实其作为疾病进展生物标志物及治疗靶点的潜力。
---
以上文献均聚焦于GPRC5D重组蛋白在靶点验证、结构解析及免疫治疗中的应用，近年发表于*NEJM*、*Nature Communications*等期刊。如需具体年份或期刊信息可进一步补充。
**Background of GPRC5D Recombinant Protein**
GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D) is a member of the orphan G protein-coupled receptor (GPCR) family, characterized by its seven transmembrane domains and structural similarity to metabotropic glutamate receptors. Initially identified through genomic studies, GPRC5D remains an understudied receptor with limited understanding of its endogenous ligands or physiological roles. It is predominantly expressed in immune and hematopoietic tissues, with notable upregulation in certain cancers, particularly multiple myeloma, making it a potential therapeutic target.
Recombinant GPRC5D protein is engineered in vitro using expression systems (e.g., mammalian or insect cells) to produce purified, functional forms of the receptor for research. This protein retains key structural features, including extracellular domains critical for ligand interaction and intracellular regions involved in downstream signaling. Its recombinant form enables studies to elucidate receptor activation mechanisms, signaling pathways (e.g., cAMP or calcium signaling), and interactions with immune cells.
Recent interest in GPRC5D stems from its role in oncology. In multiple myeloma, GPRC5D is selectively expressed on malignant plasma cells, sparing healthy tissues, which positions it as a biomarker and target for immunotherapies like bispecific antibodies or CAR-T cells. Preclinical studies using recombinant GPRC5D have facilitated the development of these therapies by enabling antigen-specific binding and cytotoxicity assays.
Despite progress, gaps persist in understanding its natural ligands, tissue-specific functions, and broader implications in immunity. Research leveraging recombinant GPRC5D continues to explore its therapeutic potential and mechanistic contributions to disease, aiming to translate findings into clinical applications.
×
